Authors: O.V. Grishchenko, V.V. Bobrytska
The objective: was to optimize the treatment of perinatal infections and improve perinatal outcomes by using macrolide with a wide spectrum of action of Doramycin (spiramycin).
Materials and methods
A retrospective analysis of data and dynamic observation of 130 pregnant women with positive results of infectological studies was carried out. I (main) group of 50 patients receiving Doramycin 3 mln 3 times a day for 10 days; II (comparison group) 40 patients receiving pulse therapy with azithromycin 1 g per day on the 1st, 7th, 14th day, III (control group) 40 patients who did not receive antibiotic therapy. The selection criteria for pregnant women for this observation were the positive results of ELISA, PCR, bacteriological studies in combination with the pathological course of the perinatal period, clinical and ultrasonographic data.
Results
Elimination of chlamydial infection, toxoplasma, pathogenic flora sensitive to macrolides was observed mainly in patients of group I treated with Doramycin. Perinatal outcomes were also significantly better among patients in the main group. In group III, which did not receive antibiotic therapy, there was a high percentage of small children, premature birth and neonatal morbidity.
Conclusion
Doramycin is an effective and safe drug, the use of which can be recommended during pregnancy, complicated by perinatal infections.
The use of Doramycin significantly improves the outcome of labor for the mother and fetus.
Key words: doramycin, spiramycin, perinatal infections, treatment.